COLUMBUS, Ohio—Avation Medical, a neuromodulation and digital health company, named Jason Whiting as its new CEO. Whiting will succeed Jill Schiaparelli, who has served in the role since 2018.
"I am excited to join the Avation Medical team as we accelerate the commercialization of this groundbreaking technology to reach patients across the U.S. by working closely with physicians and payors," Whiting said. "The ‘vivally’ system is the first non-invasive, physiologic, closed-loop neuromodulation treatment offering at-home therapy for the more than 9 million people receiving care for symptoms of overactive bladder."
Whiting brings more than 25 years of experience in the medical technology industry, in which he has aimed to drive innovation and the adoption of new technologies in the implantable, capital equipment and wearable markets. Before joining Avation Medical, Whiting served as president and VP of marketing and clinical operations at Zoll Cardiac Management Solutions.
In his new role as CEO, Whiting intends to help provide the company’s “vivally” system, a wearable bladder control therapy and digital health system that seeks to assist patients with the treatment of chronic conditions, such as overactive bladder, urge urinary incontinence and urinary urgency.
"As Avation commercially scales, Jason will bring valuable experience and leadership that we expect will accelerate growth and profitability," said Tom Shehab, MD, chairman of the Avation Medical board of directors. "Jason has successfully brought wearable technologies to market and created new categories in the (medical technology) space. On behalf of the entire board, I would like to thank Jill for her service to the organization and her role in guiding the company to this stage."
